Generex presents Ph I breast cancer vaccine trial results at ASCO

USA-based Generex Biotechnology presented the final results of its Phase I trial on its novel AE37 immunotherapeutic vaccine in breast cancer patients at the meeting of the American Society of Clinical Oncology in Chicago.

The dose escalation study on the vaccine, developed by Generex's wholly-owned subsidiary Antigen Express, concluded that it was safe and well-tolerated by patients. Two of the three subjects tested at 1000mg required a reduction in dosage because of a robust local response, despite the absence of adjuvant. The firm claims this demonstrates the inherent potency of the compound. Results of the trial will be published in the July issue of the Journal of Clinical Oncology.